MY180276A - Stable liquid formulation of amg 416 (velcalcetide) - Google Patents

Stable liquid formulation of amg 416 (velcalcetide)

Info

Publication number: MY180276A
Authority: MY; Malaysia
Prior art keywords: velcalcetide; amg; liquid formulation; stable liquid; formulation
Prior art date: 2013-06-28

Application number

MYPI2015003044A

Other languages

English (en)

Inventor

Derek Maclean

Qun Yin

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-06-28

Filing date

2014-06-27

Publication date

2020-11-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51213030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY180276(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-06-27 Application filed by Amgen Inc filed Critical Amgen Inc

2020-11-26 Publication of MY180276A publication Critical patent/MY180276A/en

Links

239000012669 liquid formulation Substances 0.000 title abstract 2
ANIAZGVDEUQPRI-ZJQCGQFWSA-N etelcalcetide Chemical compound NC(N)=NCCC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O ANIAZGVDEUQPRI-ZJQCGQFWSA-N 0.000 title 2
229950006502 etelcalcetide Drugs 0.000 title 2
108091022127 etelcalcetide hydrochloride Proteins 0.000 title 2
102000013830 Calcium-Sensing Receptors Human genes 0.000 abstract 1
108010050543 Calcium-Sensing Receptors Proteins 0.000 abstract 1
229940122985 Peptide agonist Drugs 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
- F04D—NON-POSITIVE-DISPLACEMENT PUMPS
- F04D25/00—Pumping installations or systems
- F04D25/02—Units comprising pumps and their driving means
- F04D25/06—Units comprising pumps and their driving means the pump being electrically driven
- F04D25/0606—Units comprising pumps and their driving means the pump being electrically driven the electric motor being specially adapted for integration in the pump
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
- F01D—NON-POSITIVE DISPLACEMENT MACHINES OR ENGINES, e.g. STEAM TURBINES
- F01D15/00—Adaptations of machines or engines for special use; Combinations of engines with devices driven thereby
- F01D15/10—Adaptations for driving, or combinations with, electric generators

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Endocrinology (AREA)
General Engineering & Computer Science (AREA)
Mechanical Engineering (AREA)
Oil, Petroleum & Natural Gas (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Obesity (AREA)
Hematology (AREA)
Rheumatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Investigating Or Analysing Biological Materials (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Inorganic Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MYPI2015003044A 2013-06-28 2014-06-27 Stable liquid formulation of amg 416 (velcalcetide) MY180276A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201361840618P	2013-06-28	2013-06-28

Publications (1)

Publication Number	Publication Date
MY180276A true MY180276A (en)	2020-11-26

Family

ID=51213030

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MYPI2015003044A MY180276A (en)	2013-06-28	2014-06-27	Stable liquid formulation of amg 416 (velcalcetide)

Country Status (38)

Country	Link
US (4)	US9820938B2 (fr)
EP (3)	EP3878433A1 (fr)
JP (1)	JP6027708B2 (fr)
KR (1)	KR102231957B1 (fr)
CN (2)	CN114376970A (fr)
AP (1)	AP2015008936A0 (fr)
AR (1)	AR096773A1 (fr)
AU (1)	AU2014302122B2 (fr)
CA (1)	CA2916222C (fr)
CL (1)	CL2015003738A1 (fr)
CR (2)	CR20160002A (fr)
CY (1)	CY1120811T1 (fr)
DK (1)	DK3013318T3 (fr)
EA (1)	EA030220B1 (fr)
ES (1)	ES2633989T3 (fr)
HR (1)	HRP20171092T1 (fr)
HU (1)	HUE034209T2 (fr)
IL (1)	IL243210B (fr)
JO (1)	JO3817B1 (fr)
LT (1)	LT3013318T (fr)
MA (1)	MA38724B1 (fr)
ME (1)	ME02818B (fr)
MX (1)	MX2015017952A (fr)
MY (1)	MY180276A (fr)
PE (2)	PE20160549A1 (fr)
PH (1)	PH12015502816B1 (fr)
PL (1)	PL3013318T3 (fr)
PT (1)	PT3013318T (fr)
RS (1)	RS56238B1 (fr)
SG (1)	SG11201510647TA (fr)
SI (1)	SI3013318T1 (fr)
SM (1)	SMT201700401T1 (fr)
TN (1)	TN2015000569A1 (fr)
TW (1)	TWI635874B (fr)
UA (1)	UA115373C2 (fr)
UY (1)	UY35636A (fr)
WO (1)	WO2014210489A1 (fr)
ZA (1)	ZA201600238B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20160549A1 (es)	2013-06-28	2016-06-15	Amgen Inc	Formulacion liquida estable de etelcalcetida (amg 416)
WO2015154031A1 (fr)	2014-04-03	2015-10-08	Amgen Inc.	Procédé de préparation d'amg 416
JP6783787B2 (ja) *	2015-03-26	2020-11-11	アムジェンインコーポレイテッド	エテルカルセチドの調製のための液相方法
CN106137979A (zh) *	2015-03-31	2016-11-23	深圳翰宇药业股份有限公司	一种冻干粉针剂及其制备方法
CN106928321B (zh) *	2015-12-31	2019-07-26	深圳翰宇药业股份有限公司	一种合成Etelcalcetide的方法
CN106928320B (zh) *	2015-12-31	2021-01-15	深圳翰宇药业股份有限公司	一种合成Etelcalcetide的方法
CN110054662B (zh) *	2018-01-18	2021-03-02	成都圣诺生物制药有限公司	一种固相合成Etelcalcetide的方法
WO2021231960A1 (fr)	2020-05-15	2021-11-18	Amgen Inc.	Méthodes de traitement de l'hypertrophie ventriculaire gauche
CN111925415A (zh) *	2020-08-10	2020-11-13	海南中和药业股份有限公司	一种维拉卡肽杂质的制备方法
WO2022034545A1 (fr) *	2020-08-14	2022-02-17	Aurobindo Pharma Limited	Formulations d'ételcalcetide à usage parentéral
MX2023013066A (es) *	2021-05-06	2023-11-15	Amgen Inc	Formulaciones de etelcalcetida.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6365712B1 (en)	1996-10-25	2002-04-02	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian CD97 α subunit
AT409081B (de)	2000-02-16	2002-05-27	Gebro Pharma Gmbh	Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
AU2004243531B2 (en)	2003-06-03	2009-11-05	Novo Nordisk A/S	Stabilized pharmaceutical peptide compositions
KR101308912B1 (ko) *	2003-06-03	2013-09-23	노보 노르디스크 에이/에스	안정화된 약학적 펩티드 조성물
US7265092B2 (en)	2004-09-30	2007-09-04	Kai Pharmaceuticals, Inc.	Pharmaceutical formulation
JP5645408B2 (ja) *	2006-11-16	2014-12-24	カイファーマシューティカルズインコーポレーティッド	副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド
US8067532B2 (en) *	2007-01-19	2011-11-29	Kai Pharmaceuticals, Inc.	Modifications of peptide compositions to increase stability and delivery efficiency
EP2264138B2 (fr)	2009-06-19	2023-03-08	The Procter & Gamble Company	Composition de détergent liquide pour lavage de la vaisselle à la main
EP2459208B1 (fr) *	2009-07-29	2016-09-28	Kai Pharmaceuticals, Inc.	Agents thérapeutiques pour réduire les niveaux d' hormone parathyroïdienne
EP2399604A1 (fr)	2010-06-25	2011-12-28	F. Hoffmann-La Roche AG	Nouvelle formulation d'anticorps
WO2012075375A1 (fr) *	2010-12-02	2012-06-07	Lanco Biosciences, Inc.	Administration d'hormones parathyroïdiennes par des systèmes de micro-injection
PT2717896T (pt)	2011-06-08	2016-12-23	Kai Pharmaceuticals Inc	Agentes terapêuticos para a regulação do fósforo sérico
MX355063B (es)	2011-11-10	2018-04-04	Kai Pharmaceuticals Inc	Calcimiméticos y métodos para su uso.
PE20160549A1 (es)	2013-06-28	2016-06-15	Amgen Inc	Formulacion liquida estable de etelcalcetida (amg 416)
WO2015154031A1 (fr) *	2014-04-03	2015-10-08	Amgen Inc.	Procédé de préparation d'amg 416

2014
- 2014-06-27 PE PE2015002666A patent/PE20160549A1/es unknown
- 2014-06-27 TW TW103122433A patent/TWI635874B/zh active
- 2014-06-27 AU AU2014302122A patent/AU2014302122B2/en active Active
- 2014-06-27 EA EA201690099A patent/EA030220B1/ru not_active IP Right Cessation
- 2014-06-27 SI SI201430290T patent/SI3013318T1/sl unknown
- 2014-06-27 MY MYPI2015003044A patent/MY180276A/en unknown
- 2014-06-27 UA UAA201600641A patent/UA115373C2/uk unknown
- 2014-06-27 ME MEP-2017-150A patent/ME02818B/fr unknown
- 2014-06-27 PE PE2020001772A patent/PE20210413A1/es unknown
- 2014-06-27 MX MX2015017952A patent/MX2015017952A/es active IP Right Grant
- 2014-06-27 CA CA2916222A patent/CA2916222C/fr active Active
- 2014-06-27 KR KR1020167002370A patent/KR102231957B1/ko active Active
- 2014-06-27 US US14/908,481 patent/US9820938B2/en active Active
- 2014-06-27 HU HUE14742093A patent/HUE034209T2/en unknown
- 2014-06-27 JP JP2016524250A patent/JP6027708B2/ja active Active
- 2014-06-27 WO PCT/US2014/044622 patent/WO2014210489A1/fr not_active Ceased
- 2014-06-27 EP EP21156687.2A patent/EP3878433A1/fr active Pending
- 2014-06-27 SG SG11201510647TA patent/SG11201510647TA/en unknown
- 2014-06-27 SM SM20170401T patent/SMT201700401T1/it unknown
- 2014-06-27 CN CN202111597304.7A patent/CN114376970A/zh active Pending
- 2014-06-27 CR CR20160002A patent/CR20160002A/es unknown
- 2014-06-27 AP AP2015008936A patent/AP2015008936A0/xx unknown
- 2014-06-27 CN CN201480047399.7A patent/CN105764487A/zh active Pending
- 2014-06-27 ES ES14742093.9T patent/ES2633989T3/es active Active
- 2014-06-27 PL PL14742093T patent/PL3013318T3/pl unknown
- 2014-06-27 EP EP17160312.9A patent/EP3246017B1/fr active Active
- 2014-06-27 DK DK14742093.9T patent/DK3013318T3/en active
- 2014-06-27 LT LTEP14742093.9T patent/LT3013318T/lt unknown
- 2014-06-27 PT PT147420939T patent/PT3013318T/pt unknown
- 2014-06-27 RS RS20170704A patent/RS56238B1/sr unknown
- 2014-06-27 EP EP14742093.9A patent/EP3013318B1/fr active Active
- 2014-06-27 MA MA38724A patent/MA38724B1/fr unknown
- 2014-06-27 HR HRP20171092TT patent/HRP20171092T1/hr unknown
- 2014-06-27 TN TN2015000569A patent/TN2015000569A1/en unknown
- 2014-06-27 CR CR20160061A patent/CR20160061A/es unknown
- 2014-06-29 JO JOP/2014/0204A patent/JO3817B1/ar active
- 2014-06-30 AR ARP140102450A patent/AR096773A1/es not_active Application Discontinuation
- 2014-06-30 UY UY0001035636A patent/UY35636A/es not_active Application Discontinuation
2015
- 2015-12-17 IL IL243210A patent/IL243210B/en active IP Right Grant
- 2015-12-17 PH PH12015502816A patent/PH12015502816B1/en unknown
- 2015-12-28 CL CL2015003738A patent/CL2015003738A1/es unknown
2016
- 2016-01-12 ZA ZA2016/00238A patent/ZA201600238B/en unknown
2017
- 2017-07-19 CY CY171100771T patent/CY1120811T1/el unknown
- 2017-11-02 US US15/802,390 patent/US10344765B2/en active Active
2019
- 2019-06-03 US US16/430,322 patent/US11162500B2/en active Active
2021
- 2021-08-11 US US17/400,044 patent/US11959486B2/en active Active

Also Published As

Publication number	Publication date
HK1222557A1 (en)	2017-07-07
EP3246017A1 (fr)	2017-11-22
EP3878433A1 (fr)	2021-09-15
UY35636A (es)	2015-01-30
TWI635874B (zh)	2018-09-21
AR096773A1 (es)	2016-02-03
EP3246017B1 (fr)	2021-03-24
PE20210413A1 (es)	2021-03-04
HRP20171092T1 (hr)	2017-10-06
DK3013318T3 (en)	2017-08-07
EA030220B1 (ru)	2018-07-31
RS56238B1 (sr)	2017-11-30
SG11201510647TA (en)	2016-01-28
US20180080452A1 (en)	2018-03-22
MA38724B1 (fr)	2017-11-30
US20190285074A1 (en)	2019-09-19
LT3013318T (lt)	2017-09-11
PH12015502816A1 (en)	2016-03-21
CR20160061A (es)	2016-09-28
KR20160043954A (ko)	2016-04-22
CY1120811T1 (el)	2019-12-11
HUE034209T2 (en)	2018-02-28
NZ715403A (en)	2020-10-30
US11162500B2 (en)	2021-11-02
SI3013318T1 (sl)	2017-11-30
ZA201600238B (en)	2017-05-31
BR112015032615A2 (pt)	2017-07-25
US9820938B2 (en)	2017-11-21
TW201542239A (zh)	2015-11-16
US10344765B2 (en)	2019-07-09
JO3817B1 (ar)	2021-01-31
PL3013318T3 (pl)	2018-03-30
JP2016523916A (ja)	2016-08-12
CA2916222C (fr)	2021-05-18
CN114376970A (zh)	2022-04-22
PT3013318T (pt)	2017-07-24
PH12015502816B1 (en)	2016-03-21
JP6027708B2 (ja)	2016-11-16
KR102231957B1 (ko)	2021-03-25
ME02818B (fr)	2018-01-20
MA38724A1 (fr)	2017-03-31
AP2015008936A0 (en)	2015-12-31
SMT201700401T1 (it)	2017-09-07
TN2015000569A1 (en)	2017-04-06
US20160220486A1 (en)	2016-08-04
US11959486B2 (en)	2024-04-16
CR20160002A (es)	2018-02-13
CL2015003738A1 (es)	2016-12-09
US20220042515A1 (en)	2022-02-10
CA2916222A1 (fr)	2014-12-31
EP3013318B1 (fr)	2017-04-19
CN105764487A (zh)	2016-07-13
WO2014210489A1 (fr)	2014-12-31
UA115373C2 (uk)	2017-10-25
AU2014302122B2 (en)	2018-12-06
IL243210B (en)	2020-02-27
MX2015017952A (es)	2016-10-28
EA201690099A1 (ru)	2016-06-30
ES2633989T3 (es)	2017-09-26
PE20160549A1 (es)	2016-06-15
AU2014302122A1 (en)	2016-01-21
IL243210A0 (en)	2016-02-29
EP3013318A1 (fr)	2016-05-04

Publication	Publication Date	Title
PH12015502816B1 (en)	2016-03-21	Stable liquid formulation of etelcalcetide (amg 416)
IL269499A (en)	2019-11-28	Stable antibody formulation
EP2981543A4 (fr)	2017-03-22	Nouveaux antagonistes peptidiques d' 4 7
PT3310346T (pt)	2021-04-22	Comprimido orodispersível contendo estetrol
PT3310345T (pt)	2021-05-28	Comprimido orodispersível contendo estetrol
IL245483A0 (en)	2016-06-30	Compounds to fibroblast growth factor receptor-3 (fgfr3) and therapeutic uses
EP2970418A4 (fr)	2016-08-17	Peptide d'ezh2 stabilisé
EP3121569A4 (fr)	2017-09-27	Dispositif d'alimentation de distribution et dispositif de mesure combiné
PL3791860T3 (pl)	2024-03-18	Stabilna ciekła formulacja gonadotropiny
AU2017901062A0 (en)	2017-04-06	Foot measuring device
UA88242U (ru)	2014-03-11	Применение ралейкина (антагониста рецепторов интерлейкина-1) как средства гипогликемического действия
AU2015904176A0 (en)	2015-10-29	Foot measuring device